Login to Your Account

Sublicensing Right to UCB, $30M to Immunomedics

Immunomedics, UCB Rework Agreement for Lupus Drug

By Marie Powers
Staff Writer

Thursday, December 29, 2011

Immunomedics Inc. and development partner UCB SA revised their development, collaboration and license agreement for the exclusive worldwide rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription